JPMorgan Resumes Allergen (AGN) at Overweight

UBS Cuts Allergan (AGN) PT, Ests But Remains Above Consensus

UBS analyst, Marc Goodman, cited Allergen (NYSE: AGN) as a standalone company as one of his favorites. He thinks management said all the right things regarding capital deployment, M&A aggressiveness, cost cutting, its commitment to a R&D-driven business model, and its preparedness for this contingency (i.e., a deal break).... More

Susquehanna Downgrades Allergen (AGN) to Neutral

Susquehanna downgraded Allergen (NYSE: AGN) from Positive to Neutral.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $244.74 yesterday.

Allergan (AGN) Affirms Termination of Pfizer (PFE) Merger; Affirms Strength as Standalone Company

Allergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective . In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.

Allergan reiterated its compelling standalone growth profile and strategy following the announced termination of the combination of the two companies. Allergan is positioned to drive strong, sustainable growth powered by leading franchises, new potential blockbuster product launches and unmatched pipeline.

"While we... More

Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change... More